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http://dx.doi.org/10.1016/j.ccr.2012.10.009SUMMARYBRAFV600E drives tumors by dysregulating ERK signaling. In these tumors, we show that high levels of ERK-
dependent negative feedback potently suppress ligand-dependent mitogenic signaling and Ras function.
BRAFV600E activation is Ras independent and it signals as a RAF-inhibitor-sensitive monomer. RAF inhibitors
potently inhibit RAFmonomers and ERK signaling, causing relief of ERK-dependent feedback, reactivation of
ligand-dependent signal transduction, increased Ras-GTP, and generation of RAF-inhibitor-resistant RAF
dimers. This results in a rebound in ERK activity and culminates in a new steady state, wherein ERK signaling
is elevated compared to its initial nadir after RAF inhibition. In this state, ERK signaling is RAF inhibitor resis-
tant, and MEK inhibitor sensitive, and combined inhibition results in enhancement of ERK pathway inhibition
and antitumor activity.INTRODUCTION
ERK signaling plays an important role in regulating pleiotypic
cellular functions. Activation of receptor tyrosine kinases
(RTKs) causes Ras to adopt an active, guanosine triphosphate
(GTP)-bound conformation (Downward, 2003) in which it induces
the dimerization and activation of members of the RAF kinase
family (Wellbrock et al., 2004a). Activated RAF phosphorylates
and activates MEK1/2; these phosphorylate and activate
ERK1/2, which regulate cellular function by phosphorylating
multiple substrates. A complex network of negative-feedback
interactions limits the amplitude and duration of ERK signaling.Significance
The resistance of BRAFV600E to ERK-dependent feedback is ke
inhibitors. In BRAFV600E melanomas, elevated ERK-depende
activity is low and BRAFV600E functions as a monomer. RAF
and thus are active in these tumors. However, ERK inhibition
dependent signaling, leading to a rebound in Ras activity and
dicted to determine the sensitivity of the tumor to the inhib
with MEK inhibitors or inhibitors of the relevant ligand-activate
668 Cancer Cell 22, 668–682, November 13, 2012 ª2012 Elsevier IncNegative feedback is mediated directly by ERK-dependent
inhibitory phosphorylation of components of the pathway,
including epidermal growth factor receptor (EGFR), SOS, and
RAF (Avraham and Yarden, 2011; Dougherty et al., 2005; Dou-
ville and Downward, 1997). In addition, ERK activation induces
the expression of proteins that negatively regulate the pathway,
including members of the Sprouty (Spry) and dual specificity
phosphatase (DUSP) families (Eblaghie et al., 2003; Hanafusa
et al., 2002).
ERK activation is a common feature of tumors with KRas,
NRas, or BRAF mutation, or dysregulation of RTKs (Solit and
Rosen, 2011). Tumors with BRAF mutation and some with RASy to its transforming activity and for the effectiveness of RAF
nt feedback suppresses signaling by growth factors; Ras
inhibitors potently inhibit RAF monomers, but not dimers
rapidly relieves feedback and sensitizes the cell to ligand-
ERK signaling. The degree of rebound is variable and pre-
itor. Inhibiting RAF-inhibitor-induced pathway reactivation
d receptors will be required for maximal antitumor activity.
.
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1999; Leboeuf et al., 2008; Pratilas et al., 2008; Solit et al.,
2006). However, these drugs inhibit ERK signaling in all cells,
and toxicity to normal tissue limits their dosing and their thera-
peutic effects (Kirkwood et al., 2012).
ATP-competitive RAF inhibitors have also been developed
(Bollag et al., 2010). The biologic effects of MEK inhibitors and
RAF inhibitors in BRAFV600E melanomas are similar. However,
RAF inhibitors effectively inhibit ERK signaling only in tumors
with mutant BRAF (Hatzivassiliou et al., 2010; Heidorn et al.,
2010; Joseph et al., 2010; Poulikakos et al., 2010). In cells with
wild-type (WT) BRAF, Ras activation supports the formation of
Ras-dependent RAF dimers. Binding of RAF inhibitors to one
protomer in the dimer allosterically transactivates the other and
causes activation of ERK signaling in these cells (Poulikakos
et al., 2010). We hypothesized that, in BRAFV600E tumors, levels
of Ras activity are too low to support the formation of functional
dimers, so that BRAFV600E is primarily monomeric and inhibited
by the drug. This mutation-specific pathway inhibition by the
drug gives it a broad therapeutic index and likely accounts for
its remarkable antitumor effects in melanomas with BRAF muta-
tion (Chapman et al., 2011; Sosman et al., 2012). In support of
thismodel, acquired resistance to RAF inhibitors is due to lesions
that increase Ras activity, e.g., NRASmutation or RTK activation
(Nazarian et al., 2010), and to aberrantly spliced forms of
BRAFV600E that dimerize in a Ras-independent manner (Poulika-
kos et al., 2011).
We have now endeavored to test the hypothesis that the levels
of Ras activity in BRAFV600E melanomas are too low to support
significant expression of active RAF dimers and to elucidate
the mechanism underlying this phenomenon and its biologic
and therapeutic consequences.
RESULTS
In BRAFV600E Melanomas, Ras Activation Is Suppressed
by ERK-Dependent Feedback
Assessment of BRAFV600E melanoma cells confirmed that they
have low levels of GTP-bound Ras (Figure 1A; Figure S1A avail-
able online). As expected, Ras-GTP levels were most elevated in
tumor cells with mutant Ras and were lower in cells in which ERK
signaling is driven by RTKs. Ras-GTP levels were significantly
lower in melanoma cell lines harboring BRAFV600E and could
be detected only when immunoblots were overexposed
(Figure 1A).
We investigated whether low Ras activity is due to high levels
of ERK signaling. We have shown that ERK-dependent tran-
scriptional output is markedly elevated in BRAFV600E melanomas
(Joseph et al., 2010; Pratilas et al., 2009) and includes Spry
proteins, which suppress the activation of Ras by various
RTKs. This suggests that ERK-dependent feedback inhibition
of receptor signaling causes suppression of Ras activation in
these tumors. Pharmacologic inhibition of RAF or MEK led to
induction of Ras-GTP to varying degrees in BRAFV600E tumors
(Figures 1B, 1C, and S1B), with induction beginning 4–8 hr after
drug addition and reaching a steady state 24 hr after pathway
inhibition (Figure 1B). Although marked induction of Ras-GTP
occurred, levels remained significantly lower than those
observed in tumor cells with EGFR activation (Figure S1C). TheseCanfindings show that ERK-dependent feedback suppresses Ras
activity in BRAFV600E melanomas and are consistent with the
idea that BRAFV600E signals in a Ras-independent manner.
Induction of Ras-GTP correlated with decreasing levels of
Spry proteins and the ERK phosphatase DUSP6 (Figures 1B
and S1C). Spry proteins inhibit RTK signaling, in part by binding
to Grb2 and sequestering the Grb2:SOS complex so it cannot
bind RTKs (Kim and Bar-Sagi, 2004; Mason et al., 2006). In
BRAFV600E melanomas, Spry1, 2, and 4 are overexpressed in
an ERK-dependent manner (Figure S1D). To determine whether
Spry overexpression contributes to feedback inhibition of Ras,
we knocked down the expression of Spry1, 2, and 4 with small
interfering RNA (siRNAs), and Ras-GTP was assessed 48 hr
later. Downregulation of either Spry1 or Spry2 increased total
(pan) Ras-GTP levels, whereas knockdown of Spry 4 had no
effect. Spry2 knockdown resulted in induction of HRas, NRas,
and KRas-GTP, while Spry1 and 4 downregulation appeared to
induce HRas-GTP alone (Figures 1D and S1E; data not shown).
Knockdown of all three isoforms did not result in greater induc-
tion of Ras-GTP than knockdown of Spry2 alone (Figures 1D
and S1E). Induction of Ras-GTP in these cells was associated
with increased phosphorylation of CRAFS338, a modification
associated with CRAF activation. These data suggest that
ERK-dependent feedback inhibition of Ras activation is medi-
ated, in part, by expression of Spry proteins.
We hypothesized that Spry proteins block activation of Ras by
interfering with RTK signaling. Since A375 melanoma cells
express EGFR and respond to its ligands (see below), we tested
whether the effect of Spry2 knockdown was reversed by nerati-
nib, an irreversible inhibitor of EGFR/HER kinases. Neratinib had
no effect on Ras-GTP in A375 cells, but reduced the Ras-GTP
increase induced by Spry2 knockdown (Figure 1E). This
supports the idea that ERK-dependent expression of Spry2
blocks RTK-dependent activation of Ras.
Induction of Ras-GTP by RAF Inhibitors Is Accompanied
by a Rebound in Phospho-ERK
Increased Ras-GTP should be accompanied by an increase in
RAF-inhibitor-resistant RAF dimers and a concomitant increase
in pERK and ERK signaling. After initial inhibition of ERK phos-
phorylation in seven BRAFV600E melanomas treated with the
RAF inhibitor, we observed a pronounced rebound in four cell
lines, and a more marginal rebound in two others (Figure 1F).
The pERK rebound was also elicited by dabrafenib, a more
potent RAF inhibitor (Figure S1F). The rebound was preceded
by loss of ERK-dependent inhibitory phosphorylation of CRAF
at S289, S298, and S301 and was associated with an induction
of the CRAF S338 activating phosphorylation and a slight induc-
tion of pMEK, detected in A375 cells (Figures S1F and S1G) but
not in all the cell lines.
The rebound in pERK was accompanied by increased expres-
sion of genes previously shown to be ERK-dependent in
BRAFV600E melanomas (Figures S1H–S1L). The magnitude of
pERK reactivation varied across the melanomas examined, but
pERK levels reached a steady state that was maintained for at
least 7 days (data not shown). Themagnitude of ERK reactivation
was less pronounced in melanomas than in colorectal and
thyroid carcinomas harboring BRAFV600E (J.A.F., unpublished




Figure 1. BRAFV600E Melanomas Maintain a State of Low Ras-GTP through Negative-Feedback Regulation
(A) Whole-cell lysates (WCLs) from the indicated cell lines were subjected to pull-down (PD) assays with GST-bound CRAF Ras-binding domain (RBD). WCL and
PD products were immunoblotted (IB) with a pan-Ras antibody.
(B and C) BRAF-mutated melanoma cell lines were treated with vemurafenib (2 mM) for the indicated times. Ras-GTP was detected as in (A). Phospho and total
levels of ERK pathway components were assayed by IB.
(D) A375 cells (BRAFV600E) were transfected with siRNA pools targeting the indicated Spry isoforms or scrambled oligonucleotides. WCLs were subjected to
GST-RBD PD and analyzed by IB for the indicated proteins.
(E) A375 cells were transfected with spry2 siRNA and 48 hr after transfection they were treated with neratinib (1 mM) for 1 hr. Ras-GTP levels were determined
as above.
(F) BRAFV600E melanoma cell lines were treated with vemurafenib (2 mM) for various times. The effect on ERK signaling is shown.
See also Figure S1.
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tion. Knockdown of Ras isoforms by siRNA had little effect on
baseline pERK, but decreased the residual pERK in A375 and
SkMel-28 cells treated with vemurafenib (Figure 2A). These
results confirm that ERK signaling is Ras independent in
BRAF-mutated melanomas, but that ERK rebound after RAF
inhibition is Ras dependent. Since activation of WT Ras requires
exchange factor activity, we asked whether rebound required
SOS1, a Ras-specific guanine nucleotide exchange factor that670 Cancer Cell 22, 668–682, November 13, 2012 ª2012 Elsevier Incis inhibited by Spry (Nimnual and Bar-Sagi, 2002). Down-
regulation of SOS1 in A375 cells diminished pERK rebound after
inhibition with vemurafenib without affecting baseline pERK
(Figure 2B).
ERK Rebound Is Dependent on Expression of CRAF-
Containing Dimers that Are Resistant to RAF Inhibition
Our data suggest that relief of ERK-dependent feedback inhibi-
tion of Ras activity diminishes the effect of RAF inhibitors. To.
Cancer Cell
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Ras activation and cause resistance to RAF inhibitors. The
MEK inhibitor (PD0325901) inhibited ERK phosphorylation and
induced Ras-GTP levels within 24 hr of addition (Figures 2C
and S1B). With this in mind, we asked if relief of feedback by
MEK inhibitors affected vemurafenib inhibition ofMEKphosphor-
ylation. Vemurafenib treatment for 1 hr potently inhibited pMEK
in untreated BRAFV600E melanomas and in those cells exposed
to the MEK inhibitor for up to 12 hr, at which time Ras-GTP had
not increased appreciably (Figure 2C). After 24 and 48 hr of
exposure, however, Ras-GTP was induced and inhibition of
pMEK by the RAF inhibitor was much less effective (Figures 2C
and S2A–S2C). Similar results were achieved with different
MEK (trametinib) and RAF (dabrafenib) inhibitors (Figure S2B).
These data support the idea that relief of ERK-dependent
feedback increases the level of Ras-dependent RAF dimers.
This turned out to be the case. As measured by coimmunopreci-
pitation of endogenous proteins, the MEK inhibitor increased
CRAF:BRAF dimers at times that correlated with induction of
Ras-GTP and RAF inhibitor resistance (12–48 hr, Figures 2D
and S2C).
Spry proteins suppressed RTK-induced Ras activation in
BRAFV600E melanomas. We asked if Spry expression was
required for maximal inhibition of RAF. In A375 melanoma cells,
knockdown of Spry1–4 reduced the degree of acute inhibition of
MEK phosphorylation by vemurafenib (Figure 2E). A similar result
was obtained when Spry2 was knocked down alone (Fig-
ure S2D). These findings suggest that Spry overexpression con-
tributes to maximal RAF inhibition in BRAF melanomas.
If formation of RAF dimers is responsible for rebound in ERK
phosphorylation in tumors treated with RAF inhibitors, ERK
rebound should be CRAF dependent. As previously shown (Hin-
gorani et al., 2003; Wellbrock et al., 2004b), knockdown of CRAF
expression had no effect on ERK signaling in A375 cells (Fig-
ure 2F). In contrast, in tumors treated with RAF inhibitors,
residual pERK was significantly reduced when CRAF expression
was reduced by siRNA (Figure 2F).
Together, these data suggest that relief of ERK-dependent
feedback by MEK or RAF inhibitors induces Ras-GTP and the
formation of CRAF-containing dimers that are insensitive to the
RAF inhibitor. If ERK-rebound is driven by these dimers, it should
be sensitive to MEK inhibitors, but not to RAF inhibitors (Poulika-
kos et al., 2010). We tested this assertion in BRAFV600E mela-
noma cell lines treated with vemurafenib (Figure 2G). In these
cell lines, vemurafenib caused maximal inhibition of pERK within
2 hours of inhibition, and rebound occurred within 8 hours. ERK-
rebound was insensitive to retreatment with vemurafenib, 24 hr
after the initial treatment, but was sensitive to MEK inhibition.
Similar findings were observed when the experiment was
repeated with the other MEK and RAF inhibitors (Figure S2E).
These data support the idea that relief of ERK-dependent feed-
back leads to a rebound in pERK and a new steady state in which
the pathway is driven by RAF dimers that are insensitive to RAF
inhibition.
Our data show that relief of feedback inhibition of Ras is
necessary for induction of ERK rebound. Overexpression of
the ERK phosphatase DUSP6 is a property of BRAFV600E mela-
nomas and rapidly decreases after RAF inhibition. We asked
whether downregulation of DUSP6 also contributed to ERKCanrebound. A375 cells were transfected with DUSP6-specific
siRNAs and then treated with vemurafenib. Knocking down
DUSP6 resulted in increased residual pERK following RAF
inhibition, without significant differences in residual pMEK (Fig-
ure S2F). This suggests the decrease in DUSP6 expression plays
a permissive role in pERK rebound following RAF inhibition.
We asked if relief of PI3K or mTOR pathway feedback also
affected inhibition of MEK phosphorylation by vemurafenib.
A375 cells were treated with selective inhibitors of MEK, ERK,
mTOR kinase, AKT, or PI3K for 48 hr, followed by treatment
with vemurafenib to assess inhibition of MEK phosphorylation
by RAF. Inhibiting MEK or ERK, prevented inhibition of MEK
phosphorylation by vemurafenib. This was associated with loss
of Spry2 expression and induction of CRAFS338 (Figure 2H). Inhi-
bition of PI3K, AKT, or mTOR kinase did not affect sensitivity to
vemurafenib, Spry2 expression, or pCRAF. The mTOR kinase
inhibitor did not affect vemurafenib inhibition even though it
relieved feedback inhibition of signaling to pAKTT308. Thus,
maximal effectiveness of RAF inhibitors specifically requires
intact ERK-dependent feedback.
Inhibition of ERK Rebound with MEK Inhibitors
Enhances the Suppression of ERK Output
and Tumor Growth by RAF Inhibitors
Since ERK phosphorylation and output were reactivated in
a MEK-dependent manner in tumors exposed to RAF inhibitors,
we examined whether concurrent RAF and MEK inhibition
resulted in better inhibition of the pathway and tumor growth.
As compared to treatment with either agent alone (Figure S3A),
ERK phosphorylation was inhibited to greater degree in
BRAFV600E melanomas exposed to vemurafenib and a low
concentration of PD0325901 (5 nM). The combination of dabra-
fenib and trametinib also inhibited the growth of A375 cells in
culture better than either drug alone (Figure S3B).
We tested the effectiveness of combining RAF andMEK inhib-
itors in vivo in four BRAFV600E melanoma mouse xenograft
models (Figure 3A). These experiments were done with an effec-
tive dose (12.5 mg/kg) of PLX4720, which is closely related to
vemurafenib but easier to formulate (Tsai et al., 2008), and
a low dose (2 mg/kg) of PD0325901. Each inhibitor was effective
alone (Figure 3A), with regression observed in approximately
50% of animals in either arm. In contrast, combined therapy
caused regression of all but one tumor (25/26). Figures S3C–
S3F show tumor responses over 4 weeks of treatment. The
combination of RAF and MEK inhibitors was effective in
SkMel-28 and SkMel-267 xenografts (Figures S3C and S3D). In
A375 and LOX xenografts (Figures S3E and S3F), the addition
of MEK inhibitor did not significantly improve tumor growth inhi-
bition initially, but did delay tumor regrowth following prolonged
treatment.
We repeated the experiment with a higher dose of PLX4720
(50 mg/kg) in SkMel-267 and SkMel-28 xenografts and found
that the combination of RAF andMEK inhibition was still superior
to either drug alone (Figures 3B and 3C). Flow-cytometric
analysis of tumor-derived cells from SkMel-28 xenografts
revealed that more than 50% of ERK remained phosphorylated
after single agent inhibition of RAF or MEK alone (Figure 3D).
The combination, however, resulted in a near complete ERK





Figure 2. ERK Rebound Is Dependent on Formation of CRAF-Containing Dimers that Are Resistant to RAF Inhibition
(A) BRAFV600E-expressing A375 and SkMel-28 cells were transfected with siRNA pools targeting all three Ras isoforms (+) or scrambled oligonucleotides ().
Forty-eight hours after transfection, the cells were treated with vemurafenib (2 mM) for 24 hr and analyzed by immunoblotting (IB) to detect the indicated proteins.
(B) A375 cells were transfected with siRNA pools targeting SOS1. Forty-eight hours after transfection, the cells were treated with vemurafenib (2 mM) for 24 hr and
analyzed by IB as above.
(C) A375 cells were untreated or initially pretreated with MEK inhibitor PD0325901 (50 nM) for the times shown. Subsequently, vemurafenib (1 mM) was added for
1 hr. WCLs were assayed to determine changes in pMEK and pERK. WCLs were also analyzed with a GST-RBD Elisa assay. The fold change in the amount of
GTP-bound Ras, as compared to untreated cells, is shown.
(D) BRAFV600E expressing Malme-3M cells were treated with PD0325901 (50 nM) for various times. To assess BRAF-CRAF dimerization, WCLs were subjected to
immunoprecipitation (IP) with a BRAF-specific antibody and then IB for CRAF.
(E) A375 cells were transfected with siRNA pools targeting spry1-4 genes. After 48 hr, they were treated with vemurafenib (1 mM) for 1 hr. WCLs were analyzed to
determine changes in inhibition of MEK phosphorylation.
(F) A375 cells were transfected with CRAF siRNAs and subsequently treated with vemurafenib for 24 hr. Changes in phospho and total ERK are shown.
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Figure 3. Combination of RAF and MEK Inhibitors Results in Improved Tumor Growth Inhibition In Vivo
(A) Mice bearing xenografts from four different BRAFV600E melanoma cell lines were treated with vehicle, PD0325901 (2 mg/kg), PLX4720 (12.5 mg/kg), or their
combination for 4 weeks. A waterfall representation of the best response for each tumor is shown.
(B and C) Mice bearing SkMel-267 (B) and SkMel-28 (C) xenografts were treated with PLX4720 (50 mg/kg) alone or in combination with PD0325901 (5 mg/kg) for
the indicated times. The tumor volumes (and SEM) are shown as a function of time after treatment.
(D) Cells derived from SkMel-28 xenografts treated as shown for 48 hr were subjected to flow-cytometric analysis to measure levels of pERK in isolated human
melanoma cells.
See also Figure S3.
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this is due to more complete inhibition of ERK signaling.
Relief of ERK-Dependent Feedback Potentiates
Receptor Signaling
We hypothesized that elevated ERK-dependent feedback in
these cells suppresses mitogenic signaling and causes these
cells to be poorly responsive to growth factors. If this is the
case, relief of ERK-dependent feedback by inhibitors of ERK
signaling should result in increased transduction of the ligand-
activated signal. In order to test this hypothesis, we assessed
the ability of exogenous ligands to activate signaling in
BRAFV600E cells before and after inhibition of ERK signaling
with vemurafenib (Figures 4A–4D).(G) BRAFV600E-expressing cell lines were initially treated with vemurafenib (1 mM) f
PD0325901 (5 nM, MEKi) was added for an additional 2, 8, and 24 hr, respective
(H) A375 cells were pretreated with inhibitors targeting the indicated kinases for 4
detect the ability of vemurafenib to inhibit MEK phosphorylation by RAF, as well a
Spry2 and pCRAF are also shown.
See also Figure S2.
CanBRAFV600E melanoma cells have high levels of pMEK and
pERK and high levels of expression of DUSP6 and Spry2 (Fig-
ure 4A, lane 1). After 24 hr of exposure to vemurafenib (lane 2),
pMEK and pERK are quite low, with residual levels of pERK
due to rebound. DUSP6 and Spry2 levels are markedly dimin-
ished 4–8 hr after drug exposure (lanes 7–10). To assess the
ability of an exogenous ligand to activate signaling, we added
EGF or Neuregulin (NRG) at various times after vemurafenib
treatment and evaluated signaling 10 min after ligand addition
(Figures 4A and 4B, respectively, lanes 3–10). Vemurafenib
completely suppressed pMEK and pERK within 30 min of treat-
ment and neither ligand appreciably induced pMEK, pERK,
pCRAF, or pAKT after 1 hr of RAF inhibition (lane 5). After 2 hr
of RAF inhibition, however, EGF significantly stimulated pMEKor 2, 8, and 24 hr. After 24 hr of treatment, DMSO, vemurafenib (1 mM, RAFi), or
ly. The total treatment time is indicated. The effect on ERK signaling is shown.
8 hr, followed by treatment with vemurafenib for 1 hr. WCLs were analyzed to
s the ability of the indicated compounds to inhibit their targets. Their effects on
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term ‘‘signalability,’’ rose markedly after 4–8 hr of RAF inhibition
(Figure 4A, lanes 7–8; Figure 4C), and was maintained after
24 hr of exposure to the inhibitor (lanes 9 and 10). A similar profile
of ligand-induced signaling was observed when the cells were
stimulated with NRG (Figure 4B, lanes 3–10; Figure 4D).
The ability of ligands to induce pMEK and pERK was accompa-
nied by an increase in their induction of CRAF and AKT
phosphorylation.
These data show that ligand stimulation of ERK and PI3K
signaling in BRAFV600E melanomas is low (i.e., suppressed sig-
nalability), but, hours after the ERK pathway is inhibited, the
transduction of the signal is markedly potentiated (i.e., restored
signalability). This could be due to enhanced activation of recep-
tors, enhanced signaling downstream of the activated receptor,
or both. Induction of EGFR phosphorylation after exposure to
EGF for 10 min increased slightly 1 hr after RAF inhibition, at
which time downstream signaling was not activated, and re-
mained essentially constant from 2 to 8 hr after RAF inhibition
(Figures 4A and 4C). EGFR expression did not change over
this time. These findings suggest that enhancement of EGF sig-
nalability is due to relief of feedback inhibition of intracellular
transduction of the ligand-induced signal. Of note, phospho-
and total EGFR decreased significantly 16–24 hr after RAF inhi-
bition, but induction of signaling by EGF was undiminished
(Figure 4A, lanes 9 and 10).
The ability of NRG to induce phosphorylation of HER3 was
enhanced 4 hr after RAF inhibition, while a minimal increase
was noted in the levels of HER3 protein expression (Figures 4B
and 4D). These results suggest that loss of ERK-dependent
feedback potentiates NRG activation of HER3, an event that
includes heterodimerization and phosphorylation by other HER
kinases.
To test the generality of the phenomenon of increased signal-
ability following RAF inhibition, A375 and SkMel-28 cells were
treated with vemurafenib for 24 hr and then stimulated for
10 min with EGF, NRG, epiregulin (ERG), hepatocyte growth
factor (HGF), insulin-like growth factor (IGF1), or platelet-derived
growth factor (PDGF) (Figure S4A). With the exception of IGF1
and PDGF, the ability of all of other ligands to activate ERK
was enhanced by pretreatment with vemurafenib. The effect of
RAF inhibition on receptor phosphorylation was complex (Fig-
ure S4B). Ligand-induced phosphorylation of EGFR and IGF1R
were not appreciably changed after 24 hr of ERK inhibition,
whereas phosphorylation of Met was enhanced in SkMel-28
but not in A375 cells. These data show that activation of
BRAFV600E suppresses the transduction of signaling fromFigure 4. Relief of ERK-Dependent Feedback Potentiates Receptor Si
(A–D) BRAFV600E-expressing A375 cells were treated with vemurafenib (vem, 2 mM
EGF (100 ng/ml, A) or NRG (100 ng/ml, B) for 10 min. WCLs were analyzed by im
ligand induced signaling (C and D) was determined by densitometric analysis of
(E and F) A375 cells were untreated (DMSO) or treated with vemurafenib for 1, 24
times. EGF-induced changes in phosphorylation of signaling intermediates were
were measured with an ELISA based GST-RBD assay (shown) and confirmed w
(G) A375 cells were transfected with spry2 siRNAs, followed by serum starvatio
antibodies.
(H and I) A375 cells were transfected with siRNAs targeting either SOS1 (H) or the
vemurafenib for 24 hr in serum-free media, followed by stimulation with EGF for
See also Figure S4.
Canmultiple receptors and demonstrate the complexity of the details
of this suppression in different tumors.
We characterized inmore detail the kinetics of EGF stimulation
of signaling in vemurafenib-treated A375 cells (Figures 4E and
4F). ERK is maximally inhibited after 1 hr of vemurafenib treat-
ment but EGF activation of EGFR did not activate downstream
effectors at this time. After 24 and 48 hr of vemurafenib treat-
ment, however, EGF activates MEK, ERK, AKT, and STAT3
phosphorylation. Induction of effector phosphorylation could
be blocked by HER kinase inhibitors or in the case of AKT by inhi-
bition of PI3K (data not shown).
Our data suggest that overexpression of Spry proteins
plays a role in suppressing signalability. To test this hypothesis,
we determined if knocking down Spry2 in A375 melanomas
enabled EGFR signaling. Downregulation of Spry2 induced
pCRAF and increased EGF induction of pAKT (Figure 4G).
Spry knockdown, however, did not affect EGFR-induced
pERK, consistent with the idea that loss of DUSP6 expression
is permissive for this effect. Knockdown of either SOS1 or
Ras isoforms decreased the EGF-induced activation of pCRAF,
pMEK, and pERK after 24 hr of vemurafenib treatment in A375
cells, suggesting that reactivation of ERK signaling requires
these proteins (Figures 4H and 4I, respectively, lane 8
versus 4). These data support our conclusion that Spry proteins
contribute to suppression of signalability by ERK-dependent
feedback.
Diverse Exogenous Ligands Reduce the Effectiveness
of RAF Inhibitors
Our data suggest that the response of BRAFV600E melanoma
cells to growth factors is limited. In contrast, after RAF inhibitor
treatment, the restoration of signalability enables signal trans-
duction from extracellular ligands, a process that is likely to
diminish RAF inhibition. To determine which growth factors
were capable of attenuating the antiproliferative effects of
vemurafenib, we expressed a library of 317 cDNA constructs,
encoding 220 unique secreted or single-pass transmembrane
proteins in 293T cells (Figure 5A). The media derived from these
cultures were added to BRAFV600E melanomas in combination
with vemurafenib and the effect on proliferation was assessed.
We identified more than five different ligand families (including
EGF, HGF, NRG, and FGF) that antagonized the vemurafenib
sensitivity in one or more of eight BRAFV600E melanomas tested
(Figures 5B and S5A). In contrast, other growth factors, such as
PDGF and IGF, had a minimal effect, and some, such as trans-
forming growth factor-b, accentuated vemurafenib-induced
growth inhibition. A detailed presentation of the assay for thegnaling
) for various times. At the indicated times, the cells were stimulated with either
munoblotting (IB) to assay downstream signaling. The percentage change in
the bands in (A) and (B), respectively.
, or 48 hr in serum-free media and then stimulated with EGF for the indicated
determined by IB (E) and quantified by densitometry (F). Changes in Ras-GTP
ith a traditional pull-down assay (data not shown).
n for 24 hr and EGF stimulation for 10 min. WCLs were IB with the indicated
three Ras isoforms (I) or scrambled siRNAs. Then, the cells were treated with
10 min. The phosphorylation of various signaling intermediates is shown.





Figure 5. Secreted Exogenous Ligands Reduce the Effectiveness of RAF Inhibitors
(A) Schematic representation of the secretome assay. 293T cells grown in 384-well plates were transfectedwith a cDNA library encoding 220 unique secreted and
single-pass transmembrane proteins. Secreted ligands were collected in the conditioned medium, which was combined with vemurafenib (1 mM) and added to
melanoma cell lines to assay the effect on proliferation.
(B) Heatmap representation of the effect of secreted ligands in the ability of vemurafenib to inhibit growth in a panel of eight BRAFV600E melanomas (some ligands
were encoded by multiple cDNAs). Ligands with most potent effects are shown.
(C–F) The percentage rescue by the indicated growth factors was plotted as a function of the mRNA and protein level of the respective RTK. The mRNA level was
obtained from expression profiling of the indicated lines, whereas the protein level was quantified by immunoblotting (shown in Figure S5C) and densitometry.
(G) 293H cells were transfected with V5-tagged BRAFV600E, followed by treatment with vemurafenib (1 mM, 15 min), alone, and in combination with the indicated
ligands and inhibitors (1 mM each) of HER kinases (neratinib), MET (crizotinib), or FGFR (PD173074). The ability of vemurafenib to inhibit MEK phosphorylation is
shown.
See also Figure S5.
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to vemurafenib is shown in Figure S5B.
The ability of several ligands to reduce sensitivity to vemurafe-
nib was further validated in A375, SkMel-19, and SkMel-267, in
which growth factors increased the vemurafenib IC50 (from
less than 2-fold to greater than 5-fold, Figure S5C). In contrast,
in SkMel-28 cells, the IC50 increased to greater than 5 mM in
the presence of EGF, NRG, or HGF.
We attempted to identify factors that determined whether
specific ligands (EGF, NRG, FGF, HGF) affected the vemurafe-
nib-response in these cell lines. The attenuation of vemurafenib
effect by these growth factors correlated with the level of mRNA
and protein expression of their cognate receptors (Figures 5C–
5F and S5D).
The data in Figure 4 suggest that RTK ligands will decrease
RAF inhibition by vemurafenib. To test whether this is the case
in a single cellular background, we treated 293H cells expressing
BRAFV600E with vemurafenib, in the presence or absence of EGF,
HGF, and FGF. These growth factors reduced the ability of
vemurafenib to inhibit pMEK (Figure 5G), an effect that was
reversed by inhibition of the respective RTKs, although the effect
of MET inhibitor crizotinib was modest.
HER Kinase Activity Is Upstream of ERK Rebound
In vivo, BRAFV600E melanomas may be exposed to autocrine,
paracrine, and endocrine RTK ligands. Our model suggests
that reactivation of signalability when ERK feedback is inhibited
will enable signaling from mitogenic growth factors. Since ERK
rebound occurred in A375 cells exposed to vemurafenib under
serum-free conditions (data not shown), we hypothesized that
secreted ligands were involved. To test this possibility, we
collected conditioned medium from serum-deprived A375 cells
and found that it induced ERK signaling in 293H cells, as did
EGF stimulation (Figure 6A, lanes 2 and 3). This induction was
blocked by the HER kinase inhibitor neratinib (lane 4), suggesting
that A375 cells secrete a HER kinase ligand. Furthermore,
whereas vemurafenib effectively inhibited pERK in BRAFV600E-
transfected 293H cells (lanes 5 and 6), its ability to inhibit was
reduced by A375-conditioned medium (lane 7). Under these
conditions, maximal inhibition by vemurafenib was restored
when neratinib was also added (lane 8).
To determine whether activated HER kinases support pERK
rebound in BRAFV600E cells, cells were treated for 48 hr with
vemurafenib, alone or in combination with neratinib. We found
that cotreatment with neratinib decreased ERK reactivation in
vemurafenib-treated cells but had no detectable effect on
pERK in the absence of vemurafenib (Figure 6B). Of note, nera-
tinib inhibited pEGFR without affecting pERK in the absence of
vemurafenib treatment. This confirms that while upstream
receptor activation may be required for ERK rebound, it is not
sufficient. Relief of ERK-dependent upstream feedback is the
primary cause of ERK reactivation. The receptor may be acti-
vated, but the signal is transduced effectively only when vemur-
afenib blocks ERK feedback.
In Figure 2, we show that MEK inhibition relieved feedback
inhibition of Ras, induced RAF dimerization, and decreased
the ability of vemurafenib to inhibit MEK phosphorylation. We
asked if inhibition of HER kinase signaling in this setting restored
the activity of vemurafenib. A375 and Malme-3M cells were pre-Cantreated with a MEK inhibitor (PD0325901) and/or a HER kinase
inhibitor (neratinib) for 48 hr, followed by treatment with vemur-
afenib for 1 hr. Pretreatment with the MEK inhibitor alone atten-
uated the inhibition of MEK phosphorylation by vemurafenib
(Figure 6C, lane 2 versus 6). Neratinib had no effect on ERK
signaling when given alone, but restored the ability of vemurafe-
nib to inhibit its target in cells pretreated with the MEK inhibitor
(lane 6 versus 8). This restoration was associated with
a decrease in the amount of BRAF-CRAF dimers induced by
MEK inhibitor treatment, although dimerization was not
completely abolished (Figure 6D). This suggests that while
signals originating from HER kinases attenuate the effect of
RAF inhibitors, other RTK-dependent pathways likely contribute
as well. Indeed, the attenuation of vemurafenib’s effect caused
by pretreatment with a MEK inhibitor was also reversed by inhi-
bition of FGFR. The MET inhibitor crizotinib did not affect the
ability of vemurafenib to inhibit RAF in this system, but it did
inhibit feedback-mediated activation of AKT (Figure 6E). Finally,
the inhibition of RAF by vemurafenib in combination with HER
kinase inhibitors neratinib or lapatinib caused more growth inhi-
bition in vivo than RAF inhibition alone (Figure 6F). These find-
ings together with those in Figure 3 suggest that maximizing
inhibition of ERK output by combining RAF inhibitors with inhib-
itors of ERK rebound may be required for full therapeutic
benefit.
DISCUSSION
Activation of BRAF by mutation occurs in approximately 8% of
human cancers including the majority of melanomas (Davies
et al., 2002; Badalian-Very et al., 2010; Brose et al., 2002; Nikifor-
ova et al., 2003; Schiffman et al., 2010; Tiacci et al., 2011).
Recently, ATP-competitive inhibitors of RAF kinase have been
shown to be extremely effective in the treatment of melanomas
with mutant BRAF (Chapman et al., 2011). This is thought to
occur because these drugs inhibit ERK signaling only in tumors
with mutant BRAF, whereas they induce ERK in other tumors
and normal cells (Hatzivassiliou et al., 2010; Heidorn et al.,
2010; Joseph et al., 2010; Poulikakos et al., 2010).
Induction occurs because RAF inhibitors cause transactiva-
tion of Ras-dependent RAF dimers (Poulikakos et al., 2010).
However, BRAFV600E signals as a functional monomer and RAF
inhibitors inhibit ERK signaling in this setting. We now show
that Ras activity is extremely low in BRAFV600E melanomas.
This finding confirms that BRAFV600E functions in a Ras-indepen-
dent fashion in these cells. The questions arising now are why
Ras activity is low, and whether there a causal relationship that
explains why a RAF mutant that signals as a monomer is preva-
lent in tumor cells with low Ras activity? It is possible that phys-
iologic levels of Ras-GTP are low in the normal precursor cells
from which melanomas develop. RAF mutants that require Ras
dependent dimerization would have low activity in these cells
and there would be a strong selection for a RAF mutant capable
of signaling as a monomer. Alternatively, ERK activation induces
feedback inhibition of upstream signaling, which may be suffi-
cient to potently suppress Ras activation. Here, we have demon-
strated the latter to be the case. Inhibition of ERK signaling with
either RAF or MEK inhibitors significantly induced Ras activation

































Figure 6. Targeting HER Receptor Signaling Restores Sensitivity to RAF Inhibition
(A) BRAFV600E-expressing A375 cells were grown in serum-free medium for 24 hr and the medium was collected. This conditioned medium (CM) was added to
293H cells (lanes 1–4) or to 293H cells expressing exogenous V5 tagged BRAFV600E (lanes 5–8). The cells were also treated with the indicated combinations of
CM, vemurafenib, and neratinib in order to assay the effect on ERK signaling.
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various components of ERK feedback, such as direct phosphor-
ylation of SOS and EGFR, as well as overexpression of Spry.
Here, we show that knockdown of Spry in BRAFV600E cells
increased Ras and RAF activation, and decreased the sensitivity
of the pathway to RAF inhibitors. Spry proteins, however, do not
affect the direct inhibition of SOS and CRAF by ERK, and there-
fore, even though Spry knockdown enables signaling from RTKs
to SOS, loss of Spry alone cannot account for the full effect of
ERK-dependent feedback.
Because physiologic activation of ERK is self-limited in extent
and duration (Courtois-Cox et al., 2006), one may ask how onco-
proteins cause sufficient activation of ERK output at all? We
believe that activation of ERK output requires selection of onco-
proteins that have decreased sensitivity to feedback, or second
mutations that inactivate the feedback apparatus. In fact, we
have previously shown that whereas ERK transcriptional output
is quite elevated in tumors with mutant BRAF or mutant Ras, it is
only marginally elevated in tumor cells with mutant EGFR or
amplified HER2 (Pratilas et al., 2009). In these tumors, ERK
pathway feedback is intact and levels of Ras activation are
low. In contrast, the mutant Ras protein is constitutively acti-
vated (McCormick, 1993) and it is thus refractory to feedback
inhibition of upstream signaling.
We propose that there is a powerful selection for the
BRAFV600E mutation because it signals as a Ras-independent
monomer that is insensitive to feedback. This results in marked
elevation of ERK output, with consequent feedback inhibition
of Ras-GTP. In agreement with this idea, inhibition of ERK
signaling relieves this feedback, and causes induction of Ras
activation. Ras activation is associated with a rebound in ERK
phosphorylation and output. This rebound is Ras and SOS
dependent, and more importantly, is CRAF dependent. There-
fore, while the rebound may be potentiated by the loss of ERK
phosphatases following RAF inhibition, these findings are
consistent with the idea that rebound requires reactivation of
upstream signaling and induction of RAF dimers that are refrac-
tory to RAF inhibitors but sensitive to MEK inhibition.
If RAF inhibitors cause the Ras-dependent formation of active
RAF dimers that are refractory to RAF inhibition, why do these
drugs work at all? The induction of Ras-GTP is variable in
different melanoma cell lines. It tends to be modest, however,
reaching levels that are still significantly below those found in
RTK-driven tumor cells. This results in a concomitant modest
increase in ERK phosphorylation and in ERK output. In most
melanomas, this reactivation is not sufficient to cause resis-
tance. We believe, however, that it can attenuate the effects of(B) A375 andMalme3M cells were treated with vemurafenib (1 mM) alone or in com
signaling was analyzed.
(C) The cells were pretreated with MEK inhibitor PD0325901 (901, 50 nM), and
followed by vemurafenib (1 mM) for 1 hr. Phospho- and total MEK and ERK are d
(D) The indicated cell lines were treated with PD0325901 and/or neratinib. WCLsw
BRAF and CRAF in the WCLs is shown.
(E) A375 cells were treated as in (C) but PD0325901 was combined with crizotin
(F) SkMel-28-derived xenografts were treated with combinations of PLX4720 (5
SEM) as a function of time is shown.
(G) Graphical representation of BRAFV600E melanomas adapting to RAF inhibitors
mutant BRAF in a monomeric, drug-sensitive state. Inhibition of ERK signaling ina
are resistant to RAF inhibitors, leading to bypass of inhibition and reactivation of
Cantherapy, as we find that combining RAF inhibitor with a low-
dose MEK inhibitor causes greater inhibition of pERK and ERK
output than either drug alone, and enhanced antitumor activity
in vivo in melanoma xenograft models. Thus, the variability
observed in the degree of BRAFV600E melanoma response in
patients treatedwith RAF inhibitorsmay be due in part to variable
relief of feedback. This suggests that combined inhibition could
increase the degree or duration of response obtained with RAF
inhibition alone.
Others have noted that ERK rebound is greater in BRAFV600E
thyroid (J.A.F., unpublished data) and colon (Corcoran et al.,
2012) carcinomas and is associated with resistance to the RAF
inhibitor. Recent studies show that rebound in colorectal tumors
may be associated with feedback reactivation of EGFR function
(Corcoran et al., 2012; Prahallad et al., 2012). This may explain
why RAF inhibitors have been much less effective in the treat-
ment of BRAFV600E colorectal cancer than they are in melanoma.
Prahallad et al. (2012) report that RAF inhibitors induce EGFR
activation by inhibiting the ERK-dependent CDC25C phospha-
tase and thus activating EGFR signaling in colorectal cancer
cells. Our data suggest that ERK-dependent feedback is
complex and that relief of feedback and rebound in ERK activity
is due to multiple mechanisms. In melanomas, we did not
observe an association between ERK rebound and sustained
induction of EGFR phosphorylation. Corcoran et al. (2012) also
demonstrated that ERK phosphorylation rapidly rebounds after
initial inhibition by RAF inhibitors in colorectal cancer. They
also find that this rebound is EGFR dependent and associated
with Ras activation, but not with induction of EGFR phosphory-
lation. Here, we demonstrate that relief of ERK-dependent feed-
back by RAF inhibitors results in Ras activation, induction of
CRAF-containing dimers, and RAF-inhibitor-resistant ERK
rebound. In contrast to our findings, Corcoran et al. do not
observe Ras reactivation or ERK rebound in melanomas. This
is probably because the degree of rebound is greater in colo-
rectal cancer than it is in melanoma, in which it is more difficult
to appreciate. We believe that potent ERK-dependent feedback
inhibition of signaling is a general phenomenon in tumors with
BRAFV600E and that the antitumor effects of drugs that inhibit
ERK signaling will be diminished by relief of this feedback.
It is clear that the degree of rebound varies among individual
tumors within lineages and that the rebound is greater on
average in some lineages (e.g., colorectal), than in others (e.g.,
melanoma). Although it is unlikely that this is a simple process
dependent on reactivation of a single receptor, it appears that
the process may be preferentially dependent on activation of
a particular receptor in some lineages (e.g., EGFR in colorectalbinationwith neratinib (1 mM) for 48 hr, and the effect on EGFR and downstream
HER-kinase inhibitor neratinib (Ner, 1 mM), alone or in combination for 48 hr,
etermined by IB.
ere subjected to IP with a BRAF-specific antibody and IB for CRAF. The level of
ib and PD173074 (1 mM each), targeting MET and FGFR, respectively.
0 mg/kg), neratinib (20 mg/kg), and lapatinib (150 mg/kg). Tumor growth (and
. High levels of ERK-dependent feedback suppress RTK signaling and maintain
ctivates feedback and restores RTK signaling to Ras. The resulting RAF dimers
ERK signaling.
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findings show that signaling from many receptors is suppressed
by ERK-dependent feedback in melanomas and reactivated
when feedback is relieved by ERK inhibition. It must be kept in
mind that as receptor activation of ERK increases, feedback
increases and receptor signaling declines. Each tumor reaches
a new steady state of ERK activity after RAF inhibition that
must be dependent on the level of ERK output required to induce
feedback. If feedback mechanisms are sensitive to induction by
low levels of ERK output, rebound will bemodest. If high levels of
ERK output are required to reinitiate feedback, marked ERK
rebound will occur and the tumor will be resistant. Future prog-
ress will depend on determining the lineage-dependent and
tumor-specific factors responsible for the new steady state.
Our data show that BRAFV600E melanomas are characterized
by high levels of ERK-dependent feedback that operates glob-
ally to regulate oncogenic signaling. These cells have markedly
decreased sensitivity to extracellular ligands. Indeed, the trans-
duction of signals from activated RTKs, a cellular property that
we have termed signalability, is markedly suppressed in
BRAFV600E melanomas. After ERK inhibition, however, the
ERK-dependent negative feedback is lost, and the ability of
ligands to activate signaling is markedly enhanced. This is our
key finding: at baseline these tumors are relatively insensitive
to the effects of secreted growth factors, because the ability of
such ligands to induce signaling is disabled. After administration
of drugs that effectively inhibit ERK signaling, feedback is
reduced and growth factors can signal. Thus, theymay attenuate
or prevent the antitumor effects of the inhibitor. The signaling
network is radically changed and reactivated as an adaptation
to inhibition of ERK signaling (Figure 6G).
Recently, several reports have shown that ligands, particularly
HGF, can cause resistance to RAF inhibitors (Straussman et al.,
2012; Wilson et al., 2012). Induction of signalability when ERK-
dependent feedback is relieved requires the presence of active
RTKs. We show here that multiple ligands contribute to ERK
rebound in melanomas exposed to RAF inhibitors. However,
receptor activation is permissive for induction of signalability,
i.e., necessary, but not sufficient. Rebound in ERK signaling is
due to relief of feedback inhibition of signal transduction when
ERK activation is inhibited.
In order to understand how the tumor adapts to pathway inhi-
bition and design more effective therapies, it will be necessary to
identify the pathways that become reactivated in patients, as it is
not clear that preclinical models are useful in this regard. This will
require comparison of pretreatment biopsies with biopsies
obtained hours after treatment and the development of new
technologies to determine which ligands are present and which
pathways have become reactivated. This will allow the develop-
ment of rational combination therapies aimed at inhibiting the
adaptation of the tumor to the targeted therapy.
EXPERIMENTAL PROCEDURES
Cell Lines, Antibodies, and Reagents
Cell lines were maintained as previously described (Solit et al., 2006).
Antibodies against phospho and total ERK, MEK, AKT, CRAF, HER1-3,
IGF1R, and PDGFRb were obtained from Cell Signaling; DUSP6, Spry and
Ras from Santa Cruz Biotechnology. PD0325901 was synthesized at MSKCC
organic synthesis core facility by O. Ouerfelli. Vemurafenib and PLX4720 were680 Cancer Cell 22, 668–682, November 13, 2012 ª2012 Elsevier Incprovided by Plexxikon. Trametinib and dabrafenib were obtained from
GlaxoSmithKline. Neratinib was obtained from Selleckem. Drugs for in vitro
studies were dissolved in dimethyl sulfoxide (DMSO) to yield 10 or 1 mM stock
solutions and stored at 20C.
Transfections, Immunoblotting, and Ras-GTP Assays
siRNA pools were obtained from Dharmacon and transfected into cells by
using Lipofectamine RNAiMAX, according to manufacturer’s instructions.
Cell lysis and immunoblotting were performed as described (Basso et al.,
2002). GTP-bound Ras was measured using the CRAF Ras-binding domain
(RBD) pull-down and Detection Kit (Thermo Scientific) or an ELISA-based
RBD pull-down assay (Millipore), as instructed by the manufacturers.
RT-PCR Analysis
RNA was extracted using the RNeasy Mini Kit (QIAGEN), reverse transcribed,
and used for quantitative RT-PCR, as previously described (Pratilas et al.,
2009). Relative expression of target geneswas calculated using the delta-delta
Ct method and normalized to the mRNA content of three housekeeping genes.
Animal Studies
Nu/nu athymic mice were obtained from the Harlan Laboratories and main-
tained in compliance with IACUC guidelines. Subcutaneous xenografts and
tumor measurements were performed as described (Solit et al., 2006). All
studies were performed in compliance with institutional guidelines under an
IACUC approved protocol (Memorial Sloan-Kettering Cancer Center No.
09-05-009).
Tumor Phospho-Flow Analysis
Tumors excised after 48 hr of drug exposure were homogenized and stained
with the Live/Dead Fixable Aqua Dead Cell Stain (Invitrogen) according
to manufacturer’s instructions, followed by fixation and permeabilization
and then analysis by flow cytometry with antibodies detecting HLA-ABC
(eBioscience), pERK1/2 (Cell Signaling), and APC (Southern Biotech).
Secretome Screen
A collection of 317 cDNA constructs, representing 220 unique secreted and
single-pass transmembrane proteins, were reverse transfected individually
into 293T cells using Fugene HD (Promega) in a 384-well plate format (Harbin-
ski et al., 2012). After 4 days of incubation, to allow accumulation of secreted
proteins, conditioned media from each well was transferred to the assay cells,
to which vemurafenib (1 mM)was also added. Proliferation wasmeasured 96 hr
later by using CellTiter-Glo. For each individual experiment (performed in
triplicate for each cell line) the relative light units (RLUs) were plotted as a func-
tion of the various ligand-expressing constructs. Cell growth in the absence of
vemurafenib or conditioned media (i.e., DMSO only), and in the presence of
vemurafenib alone, were used as controls. The effect (e.g., rescue) of each
ligand in the ability of vemurafenib to inhibit growth was calculated by the
formula: (median RLU for the construct  median RLU vemurafenib alone)/
median RLU DMSO. The rescue values were then used to create a heatmap
with the TIBCO Spotfire software. The relative mRNA levels were obtained
from expression analysis of the indicated cell lines (Barretina et al., 2012).
The relative protein level was determined by immunoblotting (Figure S5D)
and densitometric analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at http://dx.doi.org/10.1016/j.ccr.2012.10.009.
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